JOP20240182A1 - تحضير مثبطات تيروزين كيناز من بروتون - Google Patents
تحضير مثبطات تيروزين كيناز من بروتونInfo
- Publication number
- JOP20240182A1 JOP20240182A1 JOJO/P/2024/0182A JOP20240182A JOP20240182A1 JO P20240182 A1 JOP20240182 A1 JO P20240182A1 JO P20240182 A JOP20240182 A JO P20240182A JO P20240182 A1 JOP20240182 A1 JO P20240182A1
- Authority
- JO
- Jordan
- Prior art keywords
- proton
- preparation
- tyrosine kinase
- kinase inhibitors
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Health & Medical Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20220100151 | 2022-02-18 | ||
| EP22167032 | 2022-04-06 | ||
| EP22178413 | 2022-06-10 | ||
| PCT/EP2023/054043 WO2023156599A1 (en) | 2022-02-18 | 2023-02-17 | Synthesis of bruton's tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240182A1 true JOP20240182A1 (ar) | 2024-08-14 |
Family
ID=85227338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0182A JOP20240182A1 (ar) | 2022-02-18 | 2024-08-14 | تحضير مثبطات تيروزين كيناز من بروتون |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250163076A1 (https=) |
| EP (1) | EP4479405A1 (https=) |
| JP (1) | JP2025506671A (https=) |
| KR (1) | KR20240148351A (https=) |
| AU (1) | AU2023221549A1 (https=) |
| CA (1) | CA3252338A1 (https=) |
| CL (1) | CL2024002409A1 (https=) |
| CO (1) | CO2024011229A2 (https=) |
| IL (1) | IL314902A (https=) |
| JO (1) | JOP20240182A1 (https=) |
| MX (1) | MX2024010134A (https=) |
| PE (1) | PE20242069A1 (https=) |
| WO (1) | WO2023156599A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025262118A1 (en) * | 2024-06-20 | 2025-12-26 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2018103060A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2023
- 2023-02-17 AU AU2023221549A patent/AU2023221549A1/en active Pending
- 2023-02-17 KR KR1020247027226A patent/KR20240148351A/ko active Pending
- 2023-02-17 EP EP23705025.7A patent/EP4479405A1/en active Pending
- 2023-02-17 WO PCT/EP2023/054043 patent/WO2023156599A1/en not_active Ceased
- 2023-02-17 MX MX2024010134A patent/MX2024010134A/es unknown
- 2023-02-17 JP JP2024547937A patent/JP2025506671A/ja active Pending
- 2023-02-17 IL IL314902A patent/IL314902A/en unknown
- 2023-02-17 PE PE2024001734A patent/PE20242069A1/es unknown
- 2023-02-17 US US18/838,678 patent/US20250163076A1/en active Pending
- 2023-02-17 CA CA3252338A patent/CA3252338A1/en active Pending
-
2024
- 2024-08-12 CL CL2024002409A patent/CL2024002409A1/es unknown
- 2024-08-14 JO JOJO/P/2024/0182A patent/JOP20240182A1/ar unknown
- 2024-08-20 CO CONC2024/0011229A patent/CO2024011229A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024010134A (es) | 2024-08-27 |
| CA3252338A1 (en) | 2023-08-24 |
| KR20240148351A (ko) | 2024-10-11 |
| EP4479405A1 (en) | 2024-12-25 |
| IL314902A (en) | 2024-10-01 |
| PE20242069A1 (es) | 2024-10-18 |
| JP2025506671A (ja) | 2025-03-13 |
| CO2024011229A2 (es) | 2024-08-30 |
| US20250163076A1 (en) | 2025-05-22 |
| WO2023156599A1 (en) | 2023-08-24 |
| AU2023221549A1 (en) | 2024-10-03 |
| CL2024002409A1 (es) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230310A1 (ar) | مثبطات كيناز التيروسين للبروتون وطرق استخدامها | |
| JOP20240182A1 (ar) | تحضير مثبطات تيروزين كيناز من بروتون | |
| MX2025007434A (es) | Compuesto con anillo fusionado de pirazol, metodo de preparacion y uso del mismo | |
| DK1362047T3 (da) | Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer | |
| NO20060145L (no) | Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer | |
| ZA202304541B (en) | Cdk inhibitors and their use as pharmaceuticals | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| MX2024013215A (es) | Compuestos para inhibir kif18a | |
| BR112022018828A2 (pt) | Derivados de benzodiazepina como gaba a gamma1 pams | |
| EA202190880A1 (ru) | Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение | |
| CL2025002125A1 (es) | Compuestos novedosos | |
| MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
| CO2025018750A2 (es) | Inhibidores de wrn | |
| WO2021127482A8 (en) | Synthesis of compounds to promote hair growth | |
| MX2025001765A (es) | Derivados deuterados de pirimidin-2-il sulfonamida | |
| JOP20250299A1 (ar) | المركبات السبيرو ماكروسيكلية الناهضة لمستقبِل الأوركسين 2 | |
| CO2024011857A2 (es) | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1 | |
| EA202191995A1 (ru) | Циклические молекулы в качестве ингибитора тирозинкиназы брутона | |
| AR132456A1 (es) | Compuestos novedosos | |
| MX2025000791A (es) | Compuestos terapeuticos, formulaciones y uso de los mismos | |
| PH12022552342A1 (en) | The rad51 inhibitor compound 67a (2301085-06-1) at a specific dosage for treating cancer | |
| MX2022010675A (es) | Composiciones que comprenden profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos. | |
| WO2023049808A3 (en) | Small molecule inhibitors of tead-yap | |
| WO2019182746A3 (en) | Catalyst formulations | |
| MX2023010566A (es) | Inhibidores de proteina transportadora vesicular monoaminotransportadora-2 (vmat2) y metodos de uso. |